Simone Lista

Dr. Simone Lista


Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
12 June 2018 in Journal of Alzheimer’s Disease
Verified
Journal Article
Closed access
PDF file
HHHarald Hampel
Harald Hampel
Nicola ToschiNicola Toschi
Nicola Toschi
Claudio BabiloniClaudio Babiloni
Claudio Babiloni
FBFilippo Baldacci
Filippo Baldacci
KBKeith L. Black
Keith L. Black
SLSimone Lista
Simone Lista
The Precision Neurology development process implements systems theory with system biology and neurophysiology in a parallel, bidirectional research path: a combined hypothesis-driven investigation of systems dysfunction within distinct molecular, cellular, and large-scale neural network systems in both animal models as well as through tests for the usefulness of these candidate dynamic systems biomarkers in different diseases and subgroups at different stages of pathophysiological progression. This translational research path is paralleled by an “omics”-based, hypothesis-free, exploratory research pathway, which will collect multimodal data from progressing asymptomatic, preclinical, and clinical neurodegenerative disease (ND) populations, within the wide continuous biological and clinical spectrum of ND, applying high-throughput and high-content technologies combined with powerful computational and statistical modeling tools, aimed at identifying novel dysfunctional systems and predictive marker signatures associated with ND. The goals are to identify common biological denominators or differentiating classifiers across the continuum of ND during detectable stages of pathophysiological progression, characterize systems-based intermediate endophenotypes, validate multi-modal novel diagnostic systems biomarkers, and advance clinical intervention trial designs by utilizing systems-based intermediate endophenotypes and candidate surrogate markers. Achieving these goals is key to the ultimate development of early and effective individualized treatment of ND, such as Alzheimer’s disease. The Alzheimer Precision Medicine Initiative (APMI) and cohort program (APMI-CP), as well as the Paris based core of the Sorbonne University Clinical Research Group “Alzheimer Precision Medicine” (GRC-APM) were recently launched to facilitate the passageway from conventional clinical diagnostic and drug development toward breakthrough innovation based on the investigation of the comprehensive biological nature of aging individuals. The APMI movement is gaining momentum to systematically apply both systems neurophysiology and systems biology in exploratory translational neuroscience research on ND.

12 March 2019 in Journal of Alzheimer’s Disease
Verified
Journal Article
Closed access
PDF file
HHHarald Hampel
Harald Hampel
AVAndrea Vergallo
Andrea Vergallo
George PerryGeorge Perry
George Perry
SLSimone Lista
Simone Lista
Precision medicine (PM) is an evolving scientific renaissance movement implementing key breakthrough technological and scientific advances to overcome the limitations of traditional symptom- and sign-based phenotypic diagnoses and clinical “one-size-fits-all, magic bullet drug development” in these largely heterogeneous target populations. It is a conceptual shift from ineffective treatments for biologically heterogeneous “population averages” to individually-tailored biomarker-guided targeted therapies. PM is defining which therapeutic approach will be the most effective for a specific individual, at a determined disease stage, across multiple medical research fields, including neuroscience, neurology and psychiatry. The launch of the Alzheimer Precision Medicine Initiative (APMI) and its associated cohort program in 2016—facilitated by the academic core coordinating center run by the Sorbonne University Clinical Research Group in Alzheimer Precision Medicine (Sorbonne University GRC n°21 APM)”—is geared at transforming healthcare, conventional clinical diagnostics, and drug development research in Alzheimer’s disease. Ever since the commencement of the APMI, the international interdisciplinary research network has introduced groundbreaking translational neuroscience programs on the basis of agnostic exploratory genomics, systems biology, and systems neurophysiology applying innovative “big data science”, including breakthrough artificial intelligence-based algorithms. Here, we present the scientific breakthrough advances and the pillars of the theoretical and conceptual development leading to the APMI.

16 February 2018 in Pharmacological Research
Verified
Journal Article
Closed access
HHHarald Hampel
Harald Hampel
AVAndrea Vergallo
Andrea Vergallo
LALisi Flores Aguilar
Lisi Flores Aguilar
NBNorbert Benda
Norbert Benda
KBKarl Broich
Karl Broich
SLSimone Lista
Simone Lista

Verified
Journal Article
Open access
PDF file
SLSusana López-Ortiz
Susana López-Ortiz
Jose Pinto-FragaJose Pinto-Fraga
Jose Pinto-Fraga
Pedro L. ValenzuelaPedro L. Valenzuela
Pedro L. Valenzuela
JMJuan Martín-Hernández
Juan Martín-Hernández
MSMaría Medina Seisdedos
María Medina Seisdedos
ASAlejandro Santos-Lozano
Alejandro Santos-Lozano
Alzheimer’s disease (AD), the most common form of neurodegenerative dementia in adults worldwide, is a multifactorial and heterogeneous disorder characterized by the interaction of genetic and epigenetic factors and the dysregulation of numerous intracellular signaling and cellular/molecular pathways. The introduction of the systems biology framework is revolutionizing the study of complex diseases by allowing the identification and integration of cellular/molecular pathways and networks of interaction. Here, we reviewed the relationship between physical activity and the next pathophysiological processes involved in the risk of developing AD, based on some crucial molecular pathways and biological process dysregulated in AD: (1) Immune system and inflammation; (2) Endothelial function and cerebrovascular insufficiency; (3) Apoptosis and cell death; (4) Intercellular communication; (5) Metabolism, oxidative stress and neurotoxicity; (6) DNA damage and repair; (7) Cytoskeleton and membrane proteins; (8) Synaptic plasticity. Moreover, we highlighted the increasingly relevant role played by advanced neuroimaging technologies, including structural/functional magnetic resonance imaging, diffusion tensor imaging, and arterial spin labelling, in exploring the link between AD and physical exercise. Regular physical exercise seems to have a protective effect against AD by inhibiting different pathophysiological molecular pathways implicated in AD.

1 July 2018 in Frontiers in Neuroendocrinology
Verified
Journal Article
Closed access
HHHarald Hampel
Harald Hampel
AVAndrea Vergallo
Andrea Vergallo
FGFilippo Sean Giorgi
Filippo Sean Giorgi
SKSeung hyun Kim
Seung hyun Kim
HDHerman Depypere
Herman Depypere
SLSimone Lista
Simone Lista